Actelion files for macitentan in PAH but faces competition from Gilead and generics
This article was originally published in Scrip
Executive Summary
Actelion has submitted a new drug application (NDA) to the US FDA seeking approval for macitentan (Opsumit), a novel oral dual endothelin receptor antagonist, for the treatment of patients with pulmonary arterial hypertension (PAH).